Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Global Cancer Vaccine Market to Generate USD 13.41 Billion by 2030, Outlines a New Report by Next Move Strategy Consulting

Published

on

<!– Name:DistributionId Value:8830715 –> <!– Name:EnableQuoteCarouselOnPnr Value:True –> <!– Name:IcbCode Value:5500 –> <!– Name:CustomerId Value:1237165 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:f5d98bcd-0964-4220-a625-ed296f8cbf6b –>

New York, May 03, 2023 (GLOBE NEWSWIRE) — According to a report published by Next Move Strategy Consulting, the global Cancer Vaccine Market generated USD 5.75 billion in 2022 and is projected to generate USD 13.41 billion by 2030, witnessing a CAGR of 10.7% from 2023 to 2030. The research offers a detailed analysis regarding drivers, restraints, and opportunities to highlight changing market dynamics. Moreover, the research provides an extensive analysis of major segments and their subsegments to determine fastest-growing and highest revenue-generating segments.

Equipping the extensive analysis of each and every aspect of the market in 207 pages, accompanied by 152 tables, and 131 figures, the report aims to become a source of guidance for market players, investors, and startups as they device strategies for next few years to achieve sustainable growth.

Request a free sample: https://www.nextmsc.com/Cancer-Vaccines-Market/request-sample

Report Coverage Details
Forecast Period 2023–2030
Base Year 2022
Market Size in 2022 USD 5.75 Billion
Market Size in 2030 USD 13.4 Billion
CAGR 10.7%
No. of Pages 207
Tables  152
Figures  131
Segments covered Technology, Type, Disease Indication, End User, and Region.
Drivers Increase in Prevalence of Cancer Across the Globe
Growth in Initiatives by Governmentand International Organizations to Eliminate Cancer
Opportunities Technological advancements in the Healthcare Sector

The report offers a comprehensive analysis of the cancer vaccine market dynamics based on drivers, restraining factors, and opportunities. Rise in cases of chronic infections such as carcinogenic infections, which include human papillomavirus (HPV), hepatitis B virus, and hepatitis C virus, contribute toward growth of cancer, which, in turn, drives growth of the market.

For instance, in February 2022, the World Health Organization (WHO) announced that in 2018, around 13% of cancer cases were attributed to carcinogenic infections such as Helicobacter pylori, hepatitis B virus, hepatitis C virus, human papillomavirus (HPV), and epstein-Barr virus. Hepatitis B and C viruses are responsible for increasing risk of liver and cervical cancers, which, in turn, increases demand for cancer vaccines. However, high cost of vaccines restrains the market growth.

Lead Analyst for ‘Life Sciences & Healthcare’ at Next Move Strategy Consulting, stated that “use of artificial intelligence (AI) in diagnosing various types of cancers and developing drugs & vaccines is expected to create new opportunities for the market in the coming years.”

Buy this report directly from here: https://www.nextmsc.com/report/cancer-vaccines-market

Need a customized report, get in touch with us here: https://www.nextmsc.com/contact

North America accounted for the highest share in 2021, and is expected to dominate throughout the forecast period. This is attributed to factors such as growth in prevalence of human papilloma virus (HPV) infections, a sexually transmitted infection that leads to cervical cancer. For instance, according to the Centers for Disease Control and Prevention (CDC), around 46,143 HPV-associated cancers are diagnosed in the U.S. each year.

Moreover, Europe is estimated to witness a steady growth in the market, owing to the presence of pharmaceutical companies such as Merck and BioNTech, which are engaged in R&D for cancer vaccines to eliminate cancer in this region. For instance, in June 2021, BioNTech announced to launch BNT111 Phase 2 cancer vaccine trial. The company is evaluating its therapeutic cancer vaccine candidate BNT111 in combination with Libtayo in patients with anti-PD1-refractory or relapsed unresectable stage III or IV melanoma.

The research offers an analysis of each region and its countries based on segments and their subsegments to outline steps to be taken to consolidate presence in the cancer vaccine market. This analysis is also helpful in determining highest-revenue generating and fastest-growing segments and taking the next steps accordingly.

If you have any queries, you can inquire before purchasing: https://www.nextmsc.com/Cancer-Vaccines-Market/inquire-before-buying

The report offers an extensive analysis of competitive landscape of the global cancer vaccine market. Some of the major market players in the manufacturing of cancer vaccine are GlaxoSmithKline plc, UbiVac, Inc, Biontech, Dendreon Pharmaceuticals, Inc, Dynavax Technologies Corporation, Merck & Co., Inc, Imugene Limited, Moderna, Inc, Northwest Biotherapeutics, Inc., Oxford Vacmedix and others.

Buy a full report here: https://www.nextmsc.com/report/cancer-vaccines-market

Also, Browse Related Reports:

Cancer/Tumor Profiling Market by Technique (genomics, proteomics, metabolomics, and epigenomics), by Technology (Immunoassay, NGS, Insitu Hybridization, Mass, Spectrometry, PCR, Microarray and Others) and by Application (Research Application and Clinical Application)- Global Opportunity Analysis and Industry Forecast 2022-2030

Cancer Gene Therapy Market by Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer) – Global Opportunity Analysis and Industry Forecast, 2019 – 2030

Cancer Drug Market by Drug Class (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), and Hormonal Therapy), by Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Other)- Global Opportunity Analysis and Industry Forecast, 2020 – 2030

About Us:

Next Move Strategy Consulting is a premier market research and management consulting firm. We are committed to providing strategically-analyzed and well-documented research reports to our customers. What makes us different from the rest is our top-quality research and the obsession with turning data into knowledge by analyzing it thoroughly and providing fact-based research recommendations. We collect information from over 500 million websites, paid databases, industry journals, and one-on-one consultations with industry experts across various sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service also help our customers make critical business decisions and gain a competitive edge in the industry.

We have serviced over 1,000 customers globally, including 90% of the Fortune 500 companies over a decade. Our analysts constantly track various high-growth markets and identify hidden opportunities in each sector or industry. We provide one of the best syndicated and custom research reports across 10 different industry verticals. Our industry-standard delivery solutions range from pre-consultation to after-sales services. We offer an excellent customer experience and help our customers make strategic business decisions.


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Enghouse Video Partners With SONIFI Health To Deliver Advanced Telehealth Solutions In Hospital Rooms

Published

on

enghouse-video-partners-with-sonifi-health-to-deliver-advanced-telehealth-solutions-in-hospital-rooms

MARKHAM, ON, April 25, 2024 /PRNewswire/ — Enghouse Video, a global leader in cutting-edge video technology solutions, today announced its partnership with SONIFI Health, enhancing virtual care in hospital settings.

SONIFI Health is a leading U.S. healthcare technology company based in Sioux Falls, South Dakota. The new partnership leverages and integrates Enghouse Video room systems technology to support SONIFI Health’s commitment to expanding telehealth applications and system optimizations in hospital settings.
Enghouse’s VidyoRooms solution, a sophisticated video conferencing technology that combines both software and hardware solutions, has been fully integrated into SONIFI Health’s interactive TV systems. This integration provides up to 4K high-quality video conferencing, multi-party sessions and robust security features that ensure full compliance with healthcare regulations.
Enghouse Video offers an immersive telehealth platform to support collaborative interdisciplinary care, improved patient outcomes and cost savings. The platform is flexible and simple, delivering the reliability, interoperability, and scalability needed for today’s healthcare environment. A key strength of the partnership is its offering of back-end integrations like patient portals, medical devices, EMR, tele-sitting, remote patient observation and consultation.
“Hospitals can choose the telehealth partner that’s right for them, and we incorporate that solution with interactive TV,” said Brian Nido, SONIFI Health’s Vice President of Customer Success. “Using the hardware and systems they already have in patient rooms helps hospitals reduce costs and maximize the value of their existing investments, while benefiting both clinicians and patients.”
SONIFI Health and Enghouse Video continue to collaborate closely to further refine and enhance the telehealth solutions provided to healthcare facilities. This partnership reflects a shared commitment to leveraging technology to create smarter hospital rooms and improve patient care across the healthcare spectrum.
About Enghouse VideoEnghouse Video, part of the Enghouse Interactive division, is a subsidiary of Enghouse Systems Limited, a vertically focused software and services company traded on the Toronto Stock Exchange (TSX: ENGH). Through highly secure, scalable and flexible Cloud-based or On Prem services, we deliver one of the world’s highest quality and most innovative video platform to video-enable any application or idea. From advanced video conferencing and collaboration tools to state-of-art enterprise video management, Enghouse Video is a unique player in multiple markets, including telehealth. Learn more at www.enghousevideo.com, read our blog, or follow us on Twitter at @EnghouseVideo, on LinkedIn, and on Facebook.
About SONIFI HealthSONIFI Health provides market-leading interactive patient engagement technology proven to improve patient outcomes and staff productivity. The EHR-integrated platform is designed to enhance patient and family experiences while increasing staff satisfaction and organizations’ operational efficiencies. As part of SONIFI Solutions, Inc., the company annually supports more than 300 million end user experiences. Learn more at sonifihealth.com.
Enghouse Video Contact: Sylvain Awad, Director, Demand Generation, Enghouse Video, part of Enghouse Interactive Division, [email protected]

View original content:https://www.prnewswire.co.uk/news-releases/enghouse-video-partners-with-sonifi-health-to-deliver-advanced-telehealth-solutions-in-hospital-rooms-302126882.html

Continue Reading

Artificial Intelligence

Global Insurance Provider Selects 3CLogic to Streamline AI and Contact Center Capabilities with ServiceNow

Published

on

global-insurance-provider-selects-3clogic-to-streamline-ai-and-contact-center-capabilities-with-servicenow

Multinational Insurance Broker to deploy 3CLogic’s solution with ServiceNow’s Financial Service Operations (FSO) platform to streamline customer experiences.
ROCKVILLE, Md., April 25, 2024 /PRNewswire/ — 3CLogic, the leading Conversational AI and Contact Center solution for ServiceNow®, today announced its selection by a global insurance provider to replace its existing contact center infrastructure as part of a larger CX transformation effort. The strategic decision is designed to complement the organization’s use of ServiviceNow’s Financial Services Operations (FSO) offering leveraged across a number of its existing product lines including Customer Warranty Claims, Roadside Assistance, and Home Warranties.

Serving millions of customers worldwide with innovative insurance and protective products, the organization required a solution that would enhance its recent investment in the ServiceNow platform as it works to transform its end-to-end customer service operations. The deployment will incorporate several of 3CLogic’s AI-powered capabilities purpose-built for ServiceNow, including Conversational AI, Speech Analytics, and AI Performance & Coaching, along with integrated call transcriptions, convenient 2-way SMS, and ServiceNow-centralized contact center reporting.
“We continue to see enterprises eager to complement their existing investment in digital platforms, such as ServiceNow, with contact center features purpose-built to extend the workflows and features they already have and use,” explains Matt Durkin, VP of Global Sales at 3CLogic. “It’s no secret that organizations are already juggling too many systems, often with overlapping capabilities, which impacts ROI and operational efficiency. We’re proud to offer an alternative approach that helps simplify the technology stack while optimizing the overall operational costs and outcomes.”
Recently named to Constellation Research’s 2024 Shortlist for Digital Customer Service and Support, 3CLogic has seen global adoption of its solution by leading enterprises in healthcare, manufacturing, travel, retail, higher education, finance, non-profits, and Managed Service Providers across five continents. As a ServiceNow-certified Technology and Build partner with offerings available for ServiceNow’s IT Service Management, Customer Workflows, HR Service Delivery, and Source-to-Pay solutions, the company will be unveiling its latest set of capabilities at ServiceNow’s annual Knowledge 2024 event this May in Las Vegas.
For more information, please contact [email protected].
About 3CLogic3CLogic transforms customer and employee experiences with its leading Cloud Contact Center and AI solutions purpose-built to enhance today’s leading CRM and Customer Service Management platforms. Globally available and leveraged by the world’s leading brands, its offerings empower enterprise organizations with innovative features such as intelligent self-service, generative and Conversational AI, agent automation & coaching, and AI-powered sentiment analytics – all designed to lower operational costs, maximize ROI, and optimize each interaction across IT Service Desks, Customer Support, Sales or HR Services teams. For more information, please visit www.3clogic.com.
Logo – https://mma.prnewswire.com/media/2318845/3CLogic_logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/global-insurance-provider-selects-3clogic-to-streamline-ai-and-contact-center-capabilities-with-servicenow-302127739.html

Continue Reading

Artificial Intelligence

ScreenPoint Medical Leadership Transition: Pieter Kroese Confirmed as CEO

Published

on

screenpoint-medical-leadership-transition:-pieter-kroese-confirmed-as-ceo

Leading Breast AI Company, creator of industry-leading Transpara®, promotes from within for new CEO
NIJMEGEN, Netherlands, April 25, 2024 /PRNewswire/ — ScreenPoint Medical, today announced a significant transition in its leadership as Mark Koeniguer, the current CEO, steps down from his position. Mark served as CEO since 2022 and was instrumental in ScreenPoint’s commercial growth and success over the past 2 years.

 
 
The company’s Board of Directors has appointed Pieter Kroese as the new Chief Executive Officer effective April 25, 2024. Pieter takes the role after serving as COO of ScreenPoint for over five years. During that time, he has managed the transition of the company from an early startup to a thriving enterprise with hundreds of customers using ScreenPoint’s flagship Transpara software to support millions of scans a year.
“I am thrilled to lead ScreenPoint into its next phase of growth and innovation,” said Mr. Kroese. “I am deeply committed to building upon the strong foundation we have and continuing to work closely with our talented team to drive continued success. We are already expanding screening capacity and capability through proven reader support – we look forward to increasing our ability to support providers and women moving forward.”
Sir Michael Brady, Chairman of the Board at ScreenPoint Medical and a co-founder of the company, expressed enthusiasm about Pieter’s appointment, stating, “Pieter’s remarkable leadership qualities, coupled with his depth of knowledge of our product and industry, make him the perfect choice to lead ScreenPoint into the future. His strategic mindset and commitment to excellence align perfectly with our company mission of early breast cancer detection. Pieter has been an integral part of our growth to date and will provide seamless leadership through this transition into our next chapter for our customers, partners, and team.”
Author of “No Longer Radical” and over a hundred peer-reviewed publications on breast imaging, Dr. Rachel Brem is a Transpara user and ScreenPoint Board Member. Dr. Brem welcomed Mr. Kroese with the following: “Pieter has been an integral part of the ScreenPoint team for years. I am confident that his leadership will continue to deliver product excellence: earlier detection with outstanding reading workflow and improved patient outcomes. We continue to see these results from clinical sites all over the world, including many here in the United States. No other Breast AI solution has demonstrated the same results as Transpara, and I am confident that the team will continue to push on these frontiers under Pieter’s leadership.” 
The entire team at ScreenPoint extends its gratitude to Mark Koeniguer and wishes him every success in the future, while warmly welcoming Pieter Kroese into his new role as CEO.
About ScreenPoint Medical
ScreenPoint Medical translates cutting edge machine learning research into technology accessible by radiologists to improve screening workflow, decision confidence and breast cancer risk assessment. Transpara is trusted by radiologists globally because it has been developed by experts in machine learning and image analysis and updated with user feedback from world-renowned breast imagers.
See all the proof at: https://screenpoint-medical.com/evidence.
Photo: https://mma.prnewswire.com/media/2397831/Pieter_Kroese_CEO_ScreenPoint_Medical.jpgLogo: https://mma.prnewswire.com/media/1582198/ScreenPoint_Medical_Logo.jpg
 
 

View original content:https://www.prnewswire.co.uk/news-releases/screenpoint-medical-leadership-transition-pieter-kroese-confirmed-as-ceo-302127719.html

Continue Reading

Trending